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 Diabetes is one of the fastest growing health risks throughout the world, and the most 
notable approach to exploring the disease has been the study of different genes and 
environmental factors that affect susceptibility to type I and type II diabetes (T2D). Behind every 
diagnosis is an intricate web of differences that lead to the inability to process glucose for energy 
as a result of insulin resistance and insufficient insulin production. Even with the common 
symptoms of high blood glucose levels and metabolic dysfunction, certain populations have been 
found to carry higher risks for developing the disease than others. This raises the questions of 
how and why genes and environment can have differing effects on particular groups. Scientists 
turn to genetic linkage studies in order to answer these questions. Obesity research and genetic 
profiling are important contributors to the progress in diabetes education, and genetic 
modification has made the development of treatments possible despite the largely unknown 
genetic contributions to T2D. Type II diabetes is a complex, multifactorial disease that differs in 
genetic markers among populations including African-Americans, Japanese, and women, but 
genetic modification technology offers artificial insulin production for universal management of 
T2D despite its complexity.  
 One diagnosis of diabetes is not always comparable to another; rather, diabetes is a 
spectrum of combined causes and symptoms that exist between strictly type I and strictly type II 
in all populations. Type II diabetes is a result of metabolic dysfunction instead of the 
autoimmunity against functional insulin production that is characteristic of type I. The variance 
in the causes shows correlation with genetic and environmental factors. Because these are 
fundamentally different modes of developing diabetes, the underlying genetic variants are a 
major source of research in the effort to prevent and treat T2D. Genome wide association studies 
(GWAS) have been successful in determining the relevance and significance of over 500,000 
single nucleotide polymorphisms (SNPs); these analyses are just some of many that are 
important in distinguishing patterns of disease development, as each study analyzes different 
populations that exhibit symptoms of T2D. Single nucleotide polymorphisms in the calpain-like 
protease (CAPN10) and transcription factor 7-like 2 (TCF7L2) genes that are related to T2D are 
some of the first SNPs identified through linkage studies. CAPN10 encodes for calpain 10, which 
is a cysteine protease involved in glucose metabolism, and TCF7L2 encodes for a protein that 
acts like a transcription factor (Groop & Pociot, 2013). While the mechanisms and effects of 
these genes are not clear, the genomic analysis promotes deeper study to more finely map 
genomes, especially at these loci, in all populations. Different SNPs in the analysis of another 
gene at the B-cell lymphoma 2 (BCL2) locus encoding for an anti-apoptosis protein were also 
found to increase the T2D risk in not only African-American populations, but also Asian and 
Hispanic groups (Saxena et al., 2012). Single nucleotide polymorphisms at these loci do not 
always identify the genes associated with diabetes, but they are the main variant markers in 
genomes that are studied to understand the genetic basis of diabetes between separate 
populations.  
 Genetic determinants for diabetes analyzed in genomic studies have shown to be more 
different than similar across different populations of people. Palmer et al. (2012) performed a 
GWAS where the rs7560163 SNP in the Rho family GTPase 3 (RND3) gene that encodes for 
Rho family GTPase 3 showed a stronger, more direct correlation to T2D in African-American 
populations than in European populations. In previous GWAS, the rs7560163 SNP had not 
reached genome-wide significance, but for the meta-analysis of 6,449 African-American 
individuals in this study, the SNP was found significant (P= 7.0 x 10-9).  The major allele for 
diabetic tendencies was also found to be more prevalent in representative African samples from 
Nigeria, suggesting that the diabetic traits might be under selection in these populations and that 
the African-derived allele is more deleterious in western culture (Palmer et al., 2012). These 
findings suggest a higher risk for diabetes among African-American populations that could be 
explained by polymorphisms that are not equally present in other groups, like those of European 
descent. The SNPs that are distinct for a certain group are important indicators of evolutionary 
selective pressures that may come from descent or culture which result in one population with a 
higher rate of disease. These African-derived alleles, for example, give African-Americans a 
higher risk of T2D compared to those with the European allele in the same environment due to 
the interaction possibly between the diet and culture in the environment and the difference in 
allele type. This one SNP governs important differences between groups of European and 
African descent, but how it correlates with other polymorphisms within that gene or other parts 
of the genome related to T2D would also be important to know to fully understand differences in 
disease development.  
Even within a given population, the presence or absence of SNPs can alter disease risk, 
further complicating the study of diabetes. A study by Fujita et al. (2012) found that including 
more SNPs associated with disease risk in analysis showed more genetic determination of T2D 
in Japanese populations, suggesting that the disease risk SNPs have an additive nature. The SNP 
of fatty acid desaturase 1 (FADS1) that encodes for a fatty acid desaturase and another near 
Prospero Homeobox I (PROXI) that encodes for a homeobox transcription factor also showed 
association with risk of T2D, which is the first time this correlation has been observed (Fujita et 
al., 2012). This study analyzed nine different SNPs that were associated with T2D (P=0.0078) in 
a sample of 2632 Japanese participants with T2D and 2050 participants without. The participants 
who possessed more disease-risk SNPs exhibited a higher fasting plasma glucose levels and a 
higher risk of T2D (P=0.0017). The additive nature of these SNPs is not the same for the SNPs 
in African-American populations and may even differ between Japanese populations, but it is 
important to note that observing other minor SNPs in different groups may increase the genetic 
correlation between T2D and a certain genotype.  
On top of the array of genetic determination, the added component of interaction between 
environmental influences and these genetic dispositions in distinct groups increases the 
complexity of disease analysis. An important environmental factor associated with T2D is diet 
and, subsequently, body mass index (BMI). Body mass index can be influenced by genetic 
predispositions like metabolism, but diet and exercise are major determinants that can correlate 
BMI with diabetes. A BMI of greater than 30 kg/m2 is considered obese, and a diet high in 
carbohydrates and fats can raise BMI over time without the mediating effects of exercise. Most 
individuals with T2D are also obese and have been shown to also carry the obesity-linked FTO 
gene that encodes for the alpha-ketoglutarate-dependent dioxygenase enzyme (Dimas et al., 
2014); this gene is thought to control energy usage and intake. Because it is well established that 
obesity is correlated with the risk of T2D, the effect of body mass index (BMI) was included into 
the study by Palmer et al. (2012), and women were found to be another distinct population at risk 
for T2D. Factoring BMI into the GWAS of different loci previously known to be associated with 
diabetes showed that seven of the ten associated disease risk loci were more prevalent in women 
(Palmer et al., 2012). This is a much larger population than the previous groups of different 
ethnicities, which makes it difficult to draw direct conclusions about determinants of disease 
risk. However, accounting for BMI introduces a factor that is partially environmental and 
partially genetic. BMI can be influenced by diet, exercise, and other environmental factors like 
culture to a certain degree. Women will experience different selective pressures based on their 
reproductive roles, creating a disparity between men and women evolution of BMI related 
characteristics and subsequently risk of T2D. The correlation of BMI and disease risk 
exemplifies that groups of people can be differentiated based on environment and evolutionary 
pressures resulting in selection, and that proposes more possible influences outside of genetic 
markers that affect expression of disease.  
The numerous SNPs found to be associated with disease risk for T2D in different 
populations need selective attention to resolve the exact genetic correlation in each population, 
which makes it more difficult to form a universal cure. Sometimes these polymorphisms and 
alleles are rare, but may contribute through different interactions with the genome and the 
environment. Even with the analysis of SNPs at many genes, there lies the possibility that some 
mutations at certain loci have been overlooked or have not been found yet. Some of the 
mutations may even have a more negligible effect than predicted due to unanalyzed interactions 
with other factors (Fujita et al., 2012). All of these combined possibilities alongside factors like 
BMI that can be affected by environment and evolutionary pressures leave it difficult to treat 
every diagnosis because there is still much to be discovered in order to understand the 
physiology of T2D. The starting point for devising the closest thing to a universal cure is 
hormones involved in metabolism and energy, like insulin, because most of the genes associated 
with T2D have some role in those pathways.  
 Even with the similarity of metabolic disruption, the amount of variation in diabetes 
makes it difficult to treat and control because the genetic and environmental factors vary in 
strength and severity among all individuals. Insulin is the main target for treatment because it is 
one of the factors in the symptoms that is common among diabetics. Insulin is the key 
component in metabolizing glucose as a source of energy; it is a hormone produced by the 
pancreas that signals for cells to take up glucose from the bloodstream and break it down or store 
it as energy. Type II diabetics generally have insulin resistance where cells cannot respond to 
normal levels of insulin and therefore cannot take in glucose, resulting in high blood glucose 
levels which can ultimately lead to the need for higher levels of insulin than the body can 
produce. Insulin injections are then used to accommodate the extra insulin needed break down 
glucose. This is the most common treatment available and it has developed significantly over the 
last few decades. Although insulin injections are one of the most common forms of treatment for 
diabetes, the production of this insulin is costly and does not always work effectively for every 
diabetic. Previous methods of acquiring insulin for treatment involved extracting the insulin 
produced by other animals such as pigs, which was very expensive and often elicited allergic 
reactions. The solution to this was genetic modification of E. coli to possess the human insulin 
gene, which is effective in producing large amounts of insulin that is less expensive and safer to 
use. Genetic modification involves the insertion of a foreign gene into a new genome usually 
through plasmids in bacteria, and genetically modified organisms (GMOs) are now the main 
method of insulin production. In a study done by Boyhan et al. (2011), the DNA in tobacco and 
lettuce chloroplasts was altered to include the modified plasmid vector with the human insulin 
production and CTB-PFx3 genes to produce proinsulin with cholera toxin B (CTB). The CTB 
fusion protein helps protect the insulin during the purification process and augments its uptake 
inside the body (Boyhan & Daniell, 2011). These tobacco and lettuce plants aim to make insulin 
even more accessible and are an even cheaper way to produce larger quantities of insulin that 
would be more effective as a treatment for some diabetics. Until genetic modification can fix the 
autoimmunity and metabolic dysfunctions, new genetically modified organisms like these 
tobacco and lettuce plants as well as the common organisms already in use like E. coli are the 
main source of insulin producing technology to alleviate diabetic stress. As more studies reveal 
genetic linkage in T2D, gene therapy and individualized treatments may be used to increase 
effectiveness of treatment. 
 Research through GWAS and linkage studies on the causes and cures for T2D is quickly 
developing and integrating the study of genetic markers for disease risk usually in the form of 
SNPs. Even though these genome association studies show strong correlations between certain 
polymorphisms and diabetes, the range of alleles and SNPs is very broad among distinct 
populations. For example, the rs7560163 SNP in African-American populations and the SNPs of 
FADS1 and PROXI in Japanese populations are distinct markers from SNPs in European alleles 
and populations. The differences in these lead to alterations in disease risk that may be associated 
with evolutionary selective pressures at these loci. These genetic factors and selective pressures 
can also be influenced by environment, and that manifests itself in things such as BMI, which 
distinguishes women from men. Women are at a higher risk for T2D because of the female 
body’s ability to retain fat for reproductive periods; this results in a higher BMI which is also 
correlated to risk of T2D specifically in obese individuals. This same effect, however, can be 
achieved in other individuals or groups with high carbohydrate and fat diets, which are likely to 
be a product of environment, culture, or lifestyle.  These interactions make it even more difficult 
to distinguish causality in diabetes and to devise a cure, but the GMO market is promising in the 
field of cheaper and more effective insulin production to treat diabetes in all populations, 
regardless of ethnicity or gender. With the advancement of gene modifying techniques, 
researchers have an increasing number of options, like tobacco and lettuce leaves, to refine 
insulin production, making insulin easier to access and cheaper to produce. GMOs enable more 
diabetic populations to access insulin and are the best option for treatment until more of the 
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